When did Travere Therapeutics, Inc. report Q4 2024 earnings?

Travere Therapeutics, Inc. (TVTX) reported Q4 2024 earnings on February 20, 2025 after market close.

What were Travere Therapeutics, Inc.'s Q4 2024 revenue and EPS?

Travere Therapeutics, Inc. reported revenue of $74.8M and eps of $-0.73 for Q4 2024.

Did Travere Therapeutics, Inc. beat estimates in Q4 2024?

Revenue beat the consensus estimate of $72.4M by $2.4M. EPS missed the consensus estimate of $-0.58 by $0.15.

Where can I find Travere Therapeutics, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001438533-25-000010) directly on SEC EDGAR. The filing index links above go to sec.gov.

Travere Therapeutics, Inc. TVTX Q4 2024 Annual earnings

Reported February 20, 2025 · After market close

Revenue$74.8MBeat by $2.4M

EPS-$0.73Miss by $0.15

Revenue estimate$72.4M

EPS estimate-$0.58

Next report

Aug 5, 2026 (In 1 week)

Revenue estimate$159.2M

EPS estimate-$0.14

Financials

Q4 2024

Income statement

See full

Revenue$74.8M+66.0%

Gross profit$72.2M+78.4%

Operating income-$60.7M+35.5%

Net income-$60.3M+33.2%

EPS (diluted)-$0.71+39.8%

Balance sheet

See full

Cash & equivalents$58.5M+0.6%

Total debt$91.3M+232%

Total equity$59.1M-70.6%

Total assets$594.1M-24.7%

Cash flow

See full

Operating cash flow-$35.7M+49.3%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$1.52B+121%

Enterprise value$1.55B+136%

P/S6.5×+1.8×

Profitability

See full

Gross margin96.7%+4.6pp

Operating margin-138.9%-45.1pp

Net margin-137.9%+544pp

Returns & leverage

See full

Return on equity-247.4%-598pp

Debt / equity1.5×+1.4×

Current ratio2.1×-1.4×

Segments

By segment

See full

Reportable Segment$74.8M+106%

By product

See full

License and collaboration revenue$1.3M-75.2%

Versus estimates

Revenue

Q1 2026$127.2MMiss by $9.0M Q4 2025$129.7MMiss by $14.9M Q3 2025$164.9MBeat by $17.9M Q2 2025$114.4MBeat by $14.9M Q1 2025$81.7MMiss by $7.1M

Q4 2024$74.8MBeat by $2.4M

Diluted EPS

Q1 2026-$0.39Miss by $0.09 Q4 2025$0.03In line Q3 2025$0.28Beat by $0.59 Q2 2025-$0.14Beat by $0.14 Q1 2025-$0.47Beat by $0.08

Q4 2024-$0.73Miss by $0.15

Ask the moment Travere Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Travere Therapeutics, Inc. report Q4 2024 earnings?: Travere Therapeutics, Inc. (TVTX) reported Q4 2024 earnings on February 20, 2025 after market close.
What were Travere Therapeutics, Inc.'s Q4 2024 revenue and EPS?: Travere Therapeutics, Inc. reported revenue of $74.8M and eps of $-0.73 for Q4 2024.
Did Travere Therapeutics, Inc. beat estimates in Q4 2024?: Revenue beat the consensus estimate of $72.4M by $2.4M. EPS missed the consensus estimate of $-0.58 by $0.15.
Where can I find Travere Therapeutics, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001438533-25-000010) directly on SEC EDGAR. The filing index links above go to sec.gov.